Jan Holgersson, MD, PhD

"We are paving the way for the development of mucin-based biopharmaceuticals targeting the vaccine and anti-microbials markets."

"There are no roadmaps that we can follow to unlock the potential of mucin-based vaccines. We truly are making breakthroughs that will benefit both pharmaceutical and biotechnology companies, as well as protecting the health of people worldwide."

MD and PhD in Carbohydrate Biochemistry from the University of Gothenburg
Post-doctoral training at Harvard Medical School in Boston
Associate Professor of Molecular Immunology at Karolinska Institutet and
Clinical responsibilities as a transplant immunologist at the Karolinska University Hospital, Huddinge.

Back to researchers